Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Project Title: NHS National Framework for Tocilizumab - March 2024
Offer reference number: CM/PHR/23/5702
CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Fresenius Kabi Limited | 02182135 | ~£46,600,000 estimated from lot values | - |
| Roche Products Ltd | 00100674 | ~£46,600,000 estimated from lot values | LOBBYIST M&F Health (5 quarters) Ovid Consulting Ltd (2 quarters) |
Government spending data: These suppliers have received £218,201,939 in 4,773 payments (over £25k) from NHS Supply Chain (DHSC-funded), Department of Health and Social Care, Manchester University NHS Foundation Trust, Royal Cornwall Hospitals NHS Trust, Guy's and St Thomas' NHS FT and 13 more public bodies (2019-10-17 to 2026-03-31).